Correlation between serum hepatocyte growth factor and nonalcoholic fatty liver disease

doi:10.3877/cma.j.issn.1674-0785.2018.02.012

Abstract

Abstract:

The incidence of NAFLD keeps increasing year by year, and there are still many problems in the diagnosis and evaluation of severity of NAFLD. Pathological examination of liver tissue is still the gold standard for the diagnosis of NAFLD, and it is difficult to make a reliable diagnosis based on laboratory examination. Studies have shown that serum hepatocyte growth factor (HGF) levels are associated with NAFLD spectrum. Therefore, clarifying the relationship between HGF and NAFLD and how HGF affects the progression of NAFLD is of great significance for the further understanding of the pathogenesis, prevention and treatment of this condition. This article reviews the recent advances in understanding the correlation between HGF level and NAFLD, with an aim to provide a new approach for the clinical diagnosis of NAFLD.

Key words: Liver disease, nonalcoholic, fatty, Growth factor, hepatocyte

Xiaojuan Zheng, Fei Yang, Jinchun Liu. Correlation between serum hepatocyte growth factor and nonalcoholic fatty liver disease[J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(02): 115-118.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2018.02.012

https://zhlcyszz.cma-cmc.com.cn/EN/Y2018/V12/I02/115

References 35

1	Paolella G, Mandato C, Pierri L, et al. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease [J]. World J Gastroenterol, 2014, 20(42): 15518-15531.
2	中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版) [J]. 中华肝脏病杂志, 2010, 18(3): 163-166.
3	Fitzpatrick E, Mitry RR, Quaglia A, et al. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD [J]. J Pediatr Gastroenterol Nutr, 2010, 51(4): 500-506.
4	段晓燕, 范建高. 2010年亚太肝病学会非酒精性脂肪性肝病纪要 [J]. 实用肝脏病杂志, 2010, 13(4): 241-244.
5	Day CP, James OF. Steatohepatitis: a tale of two ″hits″? [J]. Gastroenterology, 1998, 114(4): 842-845.
6	de Luca C, Olefsky JM. Inflammation and insulin resistance [J]. FEBS Lett, 2008, 582(1): 97-105.
7	Houghton D, Stewart CJ, Day CP, et al. Gut microbiota and lifestyle interventions in NAFLD [J]. Int J Mol Sci, 2016, 17(4): 447.
8	Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more [J]. Nat Rev Mol Cell Biol, 2004, 4(12): 915-925.
9	Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats [J]. Biochem Biophys Res Commun, 1984, 122(3): 1450-1459.
10	Wolf HK, Zarnegar R, Oliver L, et al. Hepatocyte growth factor in human placenta and trophoblastic disease [J]. Am J of Pathol, 1991, 138(4): 1035-1043.
11	Shima N, Higashio K. Hepatocyte growth factor and its variant with a deletion of five amino acids are distinguishable in biological, physicochemical, and immunochemical properties [M]// Liver carcinogenesis. Springer Berlin Heidelberg, 1994.
12	Balaban YH, Sumer H, Simsek H, et al. Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF) [J]. Ann Hepatol, 2006, 5(2): 109-114.
13	Fajardo-Puerta AB, Mato Prado M, Frampton AE, et al. Gene of the month: HGF [J]. J Clin Pathol, 2016, 69(7):575-579.
14	李俊杰, 尹文, 洪楠, 等. 重组腺病毒介导HGF修饰ADSCs对大鼠肝损伤模型的治疗作用 [J]. 现代生物医学进展, 2014, 14(6): 1043-1047.
15	Maraldi T, Beretti F, Guida M, et al. Role of hepatocyte growth factor in the immunomodulation potential of amniotic fluid stem cells [J]. Stem Cells Trans Med, 2015, 4(6): 539-547.
16	Hosoya S, Ikejima K, Takeda K, et al. Innate immune responses involving natural killer and natural killer T cells promote liver regeneration after partial hepatectomy in mice [J]. Am J Physiol Gastrointes Liver Physiol, 2013, 304(3): G293-299.
17	Agrawal RP, Sheroan V, Ola V, et al. Hepatocyte growth factor, adiponectin and hepatic histopathology in non-alcoholic steatohepatitis [J]. J Assoc Physicians India, 2013, 61(11): 789-792.
18	Kroy DC, Fabienne S, Pierluigi R, et al. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic-steatohepatitis in mice [J]. J Hepatol, 2014, 61(4): 883-890.
19	He Y, Long J, Zhong W, et al. Sustained endoplasmic reticulum stress inhibits hepatocyte proliferation via downregulation of c-Met expression [J]. Mol Cell Biochem, 2014, 389(1/2): 151-158.
20	Saleem SJ, Conrad DH. Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC expansion [J]. Int Immunopharmacol, 2011, 11(7): 808-815.
21	Tojima H, Kakizaki S, Kosone T, et al. Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis [J]. Hepatol Int, 2012, 6(3): 620-630.
22	Wang D, Yu Y, Haarberg K, et al. Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice [J]. Biol Blood Marrow Transplant, 2013, 19(5): 692-702.
23	Yen BL, Yen ML, Hsu PJ, et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3 [J]. Stem Cell Reports, 2013, 1(2): 139-151.
24	Pellicoro A, Ramachandran P, Iredale JP. Reversibility of liver fibrosis [J]. Fibrogenesis Tissue Repair, 2012, 5(Suppl 1): S26.
25	Kroy DC, Schumacher F, Ramadori P, et al. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice [J]. Hepatol, 2014 , 61(4): 883-890.
26	Matsudahashii Y, Takai K, Ohta H, et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor [J]. Exp Hematol, 2004, 32(10): 955-961.
27	李旭, 齐明华. 肝内细胞上皮-间质转化:肝纤维化发生的新机制 [J]. 世界华人消化杂志, 2012, 20(10): 811-817.
28	Pinzone MR, Celesia BM, Di RM, et al. Microbial translocation in chronic liver diseases [J]. Int J Microbiol, 2012, 2012(2): 694629.
29	Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma [J]. Clin Cancer Res, 2013, 19(9): 2310-2318.
30	Osada S, Kanematsu M, Imai H, et al. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma [J]. Hepatogastroenterology, 2008, 55(82/83): 544-549.
31	Takami T, Kaposi-Novak P, Uchida K, et al. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis [J]. Cancer Res, 2007, 67(20): 9844-9851.
32	吕丽, 王莉芬, 王丽丽, 等. 肝星状细胞、肝细胞生长因子与肝癌相关性研究 [J]. 肝脏, 2005, 10(3): 213-214.
33	莫翠菊, 秦雪, 康晓楠, 等. 肝细胞生长因子(HGF)诱导肝癌Huh7细胞发生上皮间质转化(EMT)后细胞膜表面糖蛋白糖谱的变化 [J]. 复旦学报医学版, 2014, 41(2): 198-204.
34	谷艳娇, 奥瑞芳, 苏荣健. 肝细胞生长因子对肝癌细胞系SMMC-7721失巢凋亡的影响 [J]. 世界华人消化杂志, 2010, 18(8): 819-824.
35	Sattler M, Salgia R. The MET axis as a therapeutic target [J]. Update Cancer Ther, 2009, 3(3): 109-118.

Please choose a citation manager

Content to export